- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
AI in Life Science Market by Offering (End-to-End, Niche/Point, AI Tech), Application (Drug Discovery, Clinical Trials, Quality Assurance, Regulatory), Tool (Machine Learning, NLP, Computer Vision), End User (Pharma, Biotech) - Global Forecast to 2031
USD 69.34 BN
MARKET SIZE, 2031
AI IN LIFE SCIENCE MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global AI in life science market is projected to grow from USD 21.58 billion in 2026 to USD 69.34 billion by 2031, at a CAGR of 26.3% during the forecast period. The market was valued at USD 17.08 billion in 2025. This rapid growth is largely driven by the maturation of AI into clinically validated products. Evidence of this trend is evident in the rapid number of approvals and deployments of AI-based solutions within healthcare organizations. According to data published by the US FDA, more than 1,450 AI/ML-enabled medical devices had been authorized by 2025. In 2025 alone, nearly 300 approvals were granted, signaling faster commercialization of AI products. Similarly, new developments suggest increasing institutional acceptance of AI. In May 2025, the FDA announced agency-wide deployment of generative AI tools to accelerate scientific review processes, reducing tasks that previously took days to minutes. This growing regulatory acceptance and operational integration of AI are reinforcing market expansion across the life sciences ecosystem.
KEY TAKEAWAYS
-
By Region
North America accounted for the largest share of 48.9% of the AI in life science market in 2025.
-
By Offering Type
In 2025, the end-to-end solutions segment accounted for the largest share (37.5%) of the AI in life science market.
-
By Application
The clinical applications segment accounted for the largest share of the AI in life science market in 2025.
-
By Component
The software segment is projected to register the highest growth rate in the AI in life science market.
-
By End User
The pharmaceutical companies segment accounted for the largest share (37.5%) of the AI in life science market in 2025.
-
Competitive Landscape - Key Players
NVIDIA Corporation, Illumina, Inc., and Tempus AI, Inc. were identified as some of the star players in the AI in life science market, given their strong market share and product footprint.
-
Competitive Landscape - Startups/SMEs
Synthio Labs Ltd, Bioptimus, and Karyon Bio have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
Factors shaping the AI in life sciences market include the growing adoption of real-world data in clinical research, the increasing use of AI/GenAI in drug discovery and diagnostics, and the shift toward patient-centric and precision medicine models. However, challenges such as the lack of standardized validation frameworks for AI models, evolving regulatory guidelines, and concerns about data privacy, interoperability, and model reliability continue to affect the market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Al in the life sciences market is undergoing a major shift, with a growing focus on continuous, real-world data generation and passive monitoring through Al-enabled platforms. The widespread use of connected devices, electronic health records, and digital health tools is enabling continuous data capture, allowing Al models to generate deeper, more dynamic insights across the patient journey. Moreover, there is an increasing emphasis on cognitive and behavioral Al analytics, covering speech recognition, patient behavior, activity levels, and interactions. Such an approach opens up new possibilities for disease prediction, patient stratification, and long-term health monitoring. In turn, there is a shift toward the use of Al solutions in real-world applications. Namely, Al can now be used to monitor and manage conditions that do not necessarily require a visit to the doctor's office.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
-
Expanding personalized medicine
-
Growing adoption of AI-driven drug discovery
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The transformative impact of artificial intelligence on drug discovery and development is a major driver of adoption in the life sciences industry. The traditional approach to drug discovery is typically time-consuming and costly, taking more than a decade and costing hundreds of billions of dollars. AI addresses these issues by quickly and accurately identifying targets, designing molecules, and predicting drug efficacy. AI algorithms are increasingly used by pharmaceutical companies to analyze large, complex datasets, such as genomics and proteomics, to identify ideal candidates for optimization in preclinical studies. Time-to-market decreases significantly, increasing the likelihood of success in clinical trials that start early enough to identify the risks involved. With the potential to substantially decrease costs and improve outcomes, AI-driven drug discovery is emerging as a key driver of innovation in the life sciences sector, attracting significant investment and accelerating market growth.
The very high implementation cost of AI technology is a significant barrier to adoption in the life sciences market. Integrating these technologies with existing infrastructure requires upfront investment in hardware, software, and personnel. High upfront costs can substantially burden small life sciences firms or those in resource-scarce regions. The cost of acquiring and, more importantly, maintaining sophisticated AI technologies, along with the need to continually update the system or train personnel, also adds significantly to the bills. Most organizations face difficult decisions when immediate returns from such investments are limited. Therefore, though AI holds enormous promise to increase efficiency, speed drug discovery, and revolutionize patient care, its implementation cost remains a major challenge. These costs may be too high, delaying the wide-scale introduction of AI into life sciences, especially when budgets are tight and the decision to invest in AI for an extended period seems too high-risk.
One of the key drivers of AI growth in the life sciences market is the increasing use of personalized medicine. As patient data, including genetic, clinical, and lifestyle information, grows, it is increasingly analyzed with AI technologies to develop tailor-made treatments and therapies. From this information, AI can aid in pattern recognition and correlation analysis, forming a basis for developing more efficient, targeted healthcare solutions that suit each patient's specific needs. These targeted approaches lead to better patient outcomes while also making treatment procedures more efficient by reducing the trial-and-error processes that come with most forms of conventional medicine. Additionally, this will contribute to the development of new biomarkers and therapeutic targets, advancing the cause of precision medicine. There is a growing demand for more personalized healthcare solutions, and AI's role in drug development, diagnostics, and treatment planning represents a significant opportunity for innovation and growth in the life sciences industry. This shift toward personalized medicine is expected to transform healthcare delivery by making it more effective, cost-effective, and patient-centered, accelerating the adoption of AI technologies across the life sciences industry.
Data quality and integration pose the greatest challenges to AI adoption in the life sciences market. AI algorithms require large amounts of data to generate precise and meaningful insights, yet data used in life sciences are often inconsistent and fragmented. This means that siloed electronic health records, clinical trials, genomics, and wearable devices in incompatible formats make it difficult for AI to aggregate and standardize them. Health data might also be noisy, incomplete, or biased, which could result in incorrect predictions and decisions by AI. Poor-quality data can undermine effective solutions offered by AI, especially in sensitive areas such as drug development, diagnostics, and patient treatment planning. As AI is embraced in life sciences, there is an imperative need to ensure that abundant data is clean, standardized, and interoperable across all platforms and systems. Without addressing these data-related challenges, the full potential of AI in the life sciences market will remain constrained, limiting the achievement of reliable, actionable insights and further limiting the broader impact of AI in healthcare innovation.
AI IN LIFE SCIENCE MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
AI-enabled genomics platforms for sequencing data analysis, variant interpretation, and biomarker discovery | Faster genomic insights, improved precision medicine, and enhanced disease risk prediction |
|
|
AI platform integrating clinical and molecular data for oncology decision support and real-world evidence generation | Personalized treatment recommendations, improved clinical outcomes, and better research insights |
|
|
AI-driven phenomics platform combining imaging and machine learning for high-throughput drug discover | Accelerated target identification, scalable experimentation, and reduced drug discovery timelines |
|
|
AI-powered simulation platform (3DEXPERIENCE) for virtual human modeling and in-silico drug/device testing | Reduced R&D costs, faster regulatory submissions, and minimized reliance on animal testing |
|
|
Physics-based and AI-driven computational platform for molecular modeling and drug design | Improved molecule optimization, higher success rates in lead discovery, and faster pipeline progression |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The ecosystem for AI in the life sciences market comprises several stakeholder groups spanning technologies, research, and healthcare. These include providers of advanced computing technology, AI frameworks, and cloud solutions, such as NVIDIA Corporation, Microsoft Corporation, and Google Cloud. AI-based life sciences companies also specialize in developing AI-driven drug discovery or molecular modeling platforms, such as Insilico Medicine Ltd., Recursion Pharmaceuticals, Inc., and Schrodinger, Inc. Data generation and integration enablers include genomics companies, clinical data platforms, and real-world evidence providers that supply the structured or unstructured data required to train AI models. The ecosystem is completed by cloud and data infrastructure providers, such as Amazon Web Services and Google Cloud, which facilitate large-scale implementation of AI solutions. End users of these services include pharmaceutical and biotech companies, as well as contract research organizations (CROs). Key participants in the ecosystem include regulatory organizations, such as the US FDA and EMA.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The end-to-end solution subsegment has the highest market share in the AI in life sciences industry due to the rising need for platform integration, which helps simplify processes related to drug discovery, clinical research, and commercialization. End-to-end solutions support data integration, model deployment, and collaboration across departments, minimizing the complexities associated with these processes. Organizations prefer to adopt an end-to-end solution over several individual solutions due to the scalability and efficiency provided by the former approach.
It is anticipated that the clinical application segment will experience rapid growth, driven by the increased use of AI in diagnosis, clinical trial enhancement, and patient management. Artificial intelligence is revolutionizing patient acquisition, monitoring, and outcome forecasting, making clinical trials more effective and successful. Furthermore, the transition toward personalized medicine and clinical decision-making is fueling adoption. Moreover, the growing incorporation of artificial intelligence in imaging, disease detection, and overall clinical processes is boosting its role in the healthcare sector.
The software sector holds the largest market share because AI-based software applications serve as the backbone for data analytics, model building, and implementation in the life sciences. These applications enable complex analytics and automated modeling across various processes in research and clinical settings. The demand for scalable, interoperable, and easy-to-use AI software continues to grow as businesses seek to adopt AI technology in their enterprise operations. Moreover, software applications help ensure compliance with data regulations and standards, making them integral to both clinical and non-clinical segments.
The natural language processing (NLP) market will experience the fastest growth due to the growing demand for analyzing unstructured data such as clinical notes, research papers, and regulatory guidelines. The use of natural language processing technology enables efficient data processing, which will support effective decision-making during research and clinical processes. With the advent of advanced language processing models, capabilities have improved in domains such as literature mining, clinical documentation, and pharmacovigilance.
Cloud-based services have the largest market share, driven by their scalability, flexibility, and affordability when handling large and complex data sets. With cloud-based systems, there are no issues with remote collaboration, deploying AI models, or integrating multiple data sources. Cloud-based solutions also support HPC requirements necessary for AI workloads such as genomics and drug discovery. Companies now adopt a “cloud-first approach” to be more flexible and reduce infrastructure costs.
It is predicted that the biotechnology sector will grow faster due to its innovative orientation and early adoption of new technologies. Biotechnology companies are utilizing AI to carry out tasks such as target identification and molecular modeling, as well as to advance precision medicine. Given the nature of the work carried out by biotechnology companies, it is easier to incorporate AI rapidly into their operations. The increased flow of investments and collaboration with technology companies in this sector is also helping increase the use of AI.
REGION
Asia Pacific to register highest CAGR in AI in life science market during forecast period
The market for AI in the life sciences industry in the Asia Pacific region is showing rapid growth on account of the adoption of AI-enabled healthcare systems in the region. The region is witnessing a shift towards an AI-enabled healthcare system, where countries are now moving toward the implementation of AI in their healthcare system beyond piloting initiatives. One such driving factor is the increasing adoption rate within healthcare organizations. As per IDC (2026), approximately 75% of healthcare organizations in Asia Pacific anticipate increased productivity because of AI-powered systems, pointing to increased institutional adoption of AI. Moreover, as per the Philips Future Health Index 2025, 89% of healthcare professionals in Asia Pacific consider that AI could save lives due to its early intervention ability.
AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX
Illumina, Inc. (Star Player) is a key player in the AI in life sciences market, leveraging its leadership in genomics and AI-driven data analytics. Its platforms enable large-scale genomic analysis for precision medicine, biomarker discovery, and drug development, setting a benchmark for data-driven innovation. Dassault Systèmes (Emerging Leader) is expanding in the market through AI-powered simulation and its 3DEXPERIENCE platform for virtual human modeling and in-silico development. While Illumina leads with strong genomics capabilities, it faces growing competition from players like Dassault Systèmes advancing AI-based simulation in life sciences.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- NVIDIA Corporation (US)
- Illumina, Inc. (US)
- Tempus AI, Inc. (US)
- Recursion Pharmaceuticals, Inc. (US)
- Dassault Systèmes SE (France)
- Schrödinger, Inc. (US)
- Data4Cure, Inc. (US)
- Microsoft Corporation (US)
- Insilico Medicine Ltd. (Hong Kong)
- BenevolentAI Limited (UK)
- Owkin, Inc. (France)
- PathAI, Inc. (US)
- Aidoc Medical Ltd. (Israel)
- Qure.ai Technologies Pvt. Ltd. (India)
- Deep Genomics Inc. (Canada)
- SOPHiA GENETICS SA (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 | USD 17.08 Billion |
| Market Size in 2026 | USD 21.58 Billion |
| Market Forecast in 2031 | USD 69.34 Billion |
| CAGR | 26.3% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | USD Billion |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Middle East & Africa, Latin America |
WHAT IS IN IT FOR YOU: AI IN LIFE SCIENCE MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Mapping | In-depth analysis of key AI in life sciences companies, their platforms, solutions, and market positioning across drug discovery, clinical development, diagnostics, and real-world data analytics, along with evaluation of AI technologies such as ML, NLP, and computer vision | Enables benchmarking of AI capabilities, identifies differentiation opportunities across platforms and technologies, and supports strategic partnerships, licensing, and M&A decision-making |
| Market Entry & Growth Strategy | Regional and segment-level assessment of the AI in life sciences market, including adoption trends, healthcare infrastructure maturity, investment landscape, and regulatory acceptance across pharmaceutical, biotech, and healthcare sectors | Reduces go-to-market risk, accelerates adoption through localized strategies, and supports expansion into high-growth regions and emerging AI-driven healthcare ecosystems |
| Regulatory & Operational Risk Analysis | Evaluation of compliance requirements for AI in life sciences, including FDA, EMA, HIPAA, GDPR, and emerging AI-specific regulations, along with considerations for data governance, model validation, explainability, and ethical AI use in clinical and research settings | Supports regulatory readiness, mitigates operational and compliance risks, and enhances credibility in AI-driven clinical and research applications while ensuring alignment with patient safety and data privacy standards |
| Technology Adoption Trends | Insights into the adoption of AI technologies across life sciences, including AI-driven drug discovery, clinical trial optimization, diagnostics, real-world evidence generation, and integration of multi-omics and clinical datasets with advanced analytics | Guides R&D prioritization, informs investment in AI platforms and infrastructure, and helps organizations align AI strategies with improved clinical outcomes, operational efficiency, and data-driven decision-making |
RECENT DEVELOPMENTS
- June 2024 : Medidata, a Dassault Systèmes brand, launched Medidata Clinical Data Studio, a unified platform enhancing clinical research data management. This innovation empowered stakeholders to improve data quality and accelerate safer trials for patients.
- April 2024 : IQVIA and Salesforce, the leading Al-powered CRM, announced an expanded partnership to advance Salesforce's Life Sciences Cloud, a next-generation customer engagement platform for the life sciences sector.
- March 2024 : Clarivate Plc announced an agreement to acquire most assets of MotionHall, a Silicon Valley startup specializing in AI solutions for life sciences. This move aligns with Clarivate's strategy to enhance its Life Sciences & Healthcare offerings through generative AI and proprietary industry-focused solutions.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
48
4.2.1.1
SURGING DEMAND FOR ACCELERATED DRUG DISCOVERY AND R&D PIPELINE OPTIMIZATION
4.2.1.2
GROWING CROSS-INDUSTRY PARTNERSHIPS
4.2.1.3
EXPANDING APPLICATIONS OF AI IN CLINICAL TRIAL DESIGN, PATIENT RECRUITMENT, AND OPERATIONAL EFFICIENCY
4.2.1.4
GROWING AVAILABILITY OF LARGE-SCALE BIOMEDICAL DATASETS AND ADVANCES IN COMPUTING INFRASTRUCTURE
4.2.1.5
SUPPORTIVE GOVERNMENT POLICIES, FUNDING INITIATIVES, AND REGULATORY FRAMEWORKS
4.2.2.1
DATA PRIVACY AND CYBERSECURITY CONCERNS
4.2.2.2
ALGORITHMIC BIAS AND CLINICIAN TRUST DEFICITS
4.2.2.3
HIGH IMPLEMENTATION COSTS, TECHNICAL COMPLEXITY, AND INTEGRATION CHALLENGES WITH LEGACY IT SYSTEMS
4.2.3.1
GENERATIVE AI AND FOUNDATION MODELS FOR DE NOVO DRUG DESIGN
4.2.3.2
RISING FOCUS ON RARE DISEASE TREATMENTS
4.2.3.3
GROWING DEMAND FOR PRECISION AND PERSONALIZED MEDICINE
4.2.3.4
AI INTEGRATION IN ACADEMIC RESEARCH INSTITUTES AND GOVERNMENT-BACKED BIOMEDICAL INNOVATION PROGRAMS
4.2.4.1
LOW DATA FRAGMENTATION, INTEROPERABILITY DEFICITS
4.2.4.2
TALENT SCARCITY AND ORGANIZATIONAL READINESS
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
58
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
BARGAINING POWER OF SUPPLIERS
5.1.2
BARGAINING POWER OF BUYERS
5.1.3
THREAT OF SUBSTITUTES
5.1.4
THREAT OF NEW ENTRANTS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.5.1
INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET (2025)
5.5.2
INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET, BY REGION (2025)
5.6
KEY CONFERENCES AND EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8
INVESTMENT AND FUNDING SCENARIO
5.10
IMPACT OF 2025 US TARIFF – AI IN LIFE SCIENCE MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRY/REGION
5.10.5
IMPACT ON END USERS
5.10.5.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.10.5.3
RESEARCH CENTERS & ACADEMIC INSTITUTES
5.10.5.4
DIAGNOSTIC COMPANIES
6
REGULATORY LANDSCAPE
73
6.1
REGIONAL REGULATIONS AND COMPLIANCE
6.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.1.5
MIDDLE EAST & AFRICA
7
STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
81
7.1
KEY EMERGING TECHNOLOGIES
7.1.1
GRAPH NEURAL NETWORKS
7.1.3
PREDICTIVE ANALYTICS
7.2
COMPLEMENTARY TECHNOLOGIES
7.2.1
NEXT-GENERATION SEQUENCING
7.2.2
REAL-WORLD EVIDENCE/REAL-WORLD DATA
7.2.3
PERSONALIZATION ENGINES
7.3
ADJACENT TECHNOLOGIES
7.3.3
BIG DATA & ADVANCED ANALYTICS
7.4
TECHNOLOGY/PRODUCT ROADMAP
7.5.1
INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
7.6.1
AI-DRIVEN DRUG DISCOVERY
7.6.4
VIRTUAL DRUG SCREENING
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
88
8.2
DECISION-MAKING PROCESS
8.3
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5.2
END USER EXPECTATIONS
9
AI IN LIFE SCIENCE MARKET, BY TOOL
94
9.2.1.1
CONVOLUTIONAL NEURAL NETWORKS
9.2.1.1.1
HIGH-SENSITIVITY MEDICAL IMAGING AI ACROSS ONCOLOGY AND RADIOLOGY PATHWAYS – KEY DRIVER
9.2.1.2
RECURRENT NEURAL NETWORKS
9.2.1.2.1
SEQUENTIAL BIOLOGICAL DATA PROCESSING DRIVES ADOPTION IN CLINICAL AND GENOMIC APPLICATIONS
9.2.1.3
GENERATIVE ADVERSARIAL NETWORKS
9.2.1.3.1
SYNTHETIC DATA GENERATION TO OVERCOME LIFE SCIENCE DATA SCARCITY BARRIERS BOOSTS ADOPTION
9.2.1.4
GRAPH NEURAL NETWORKS
9.2.1.4.1
GRAPH AI ARCHITECTURES MODELING MOLECULAR INTERACTIONS TO ADVANCE TARGET AND PATHWAY DISCOVERY
9.2.1.5.1
TRANSFORMER AND DIFFUSION ARCHITECTURES EXPANDING DEEP LEARNING FRONTIERS IN LIFE SCIENCES
9.2.2
SUPERVISED LEARNING
9.2.2.1
SEGMENT DRIVEN BY ACCURATE PREDICTION OF COMPOUND POTENCY AND SELECTIVITY ACROSS DIVERSE CHEMICAL SERIES
9.2.3
REINFORCEMENT LEARNING
9.2.3.1
OPTIMIZED DRUG DOSING, TRIAL DESIGN, AND AUTONOMOUS LABORATORY SYSTEMS TO DRIVE SEGMENT
9.2.4
UNSUPERVISED LEARNING
9.2.4.1
UNSUPERVISED AI REVEALING HIDDEN BIOLOGICAL PATTERNS WITHIN HIGH-DIMENSIONAL OMICS DATASETS
9.2.5
OTHER MACHINE LEARNING TECHNOLOGIES
9.2.5.1
SEMI-SUPERVISED AND FEDERATED LEARNING OVERCOME DATA SCARCITY AND PRIVACY CONSTRAINTS
9.3
NATURAL LANGUAGE PROCESSING
9.3.1
BIOMEDICAL LLMS AND CLINICAL NLP AUTOMATING KNOWLEDGE EXTRACTION FROM UNSTRUCTURED HEALTH DATA
9.4
CONTEXT-AWARE PROCESSING AND COMPUTING
9.4.1
SEGMENT DRIVEN BY DYNAMIC, PATIENT-SPECIFIC INSIGHTS ACROSS CLINICAL WORKFLOWS
9.5.1
TRANSFORMATION OF PATHOLOGY, DERMATOLOGY, AND DRUG MANUFACTURING INSPECTION PROCESSES – KEY DRIVERS
9.6.1
ACCELERATED DIGITAL PATHOLOGY, LAB IMAGING, AND DOCUMENT PROCESSING TO BOOST ADOPTION
10
AI IN LIFE SCIENCE MARKET, BY APPLICATION
113
10.2
CLINICAL APPLICATIONS
10.2.1
REDUCED DEVELOPMENT TIMELINES AND IMPROVED CLINICAL SUCCESS TO DRIVE SEGMENT
10.2.2.1
AI-DRIVEN TARGET IDENTIFICATION TRANSFORMING BIOPHARMA R&D PRODUCTIVITY AND SUCCESS RATES
10.2.3
MEDICAL IMAGING & DIAGNOSTICS
10.2.3.1
ACCELERATING FDA CLEARANCES AND RADIOLOGY DIGITIZATION DRIVES CLINICAL AI IMAGING ADOPTION
10.2.4.1
AI-POWERED TRIAL OPTIMIZATION AND DECENTRALIZED MODELS ACCELERATING PATIENT-CENTRIC RESEARCH
10.2.5
PRECISION MEDICINE
10.2.5.1
MULTI-OMICS AI INTEGRATION ENABLING INDIVIDUALIZED THERAPY SELECTION AT POPULATION SCALE
10.2.6
OTHER CLINICAL APPLICATIONS
10.2.6.1
AI-AUGMENTED CLINICAL DECISION SUPPORT EXPANDING INTO PHARMACOVIGILANCE AND RARE DISEASE
10.3
NON-CLINICAL APPLICATIONS
10.3.1.1
AI-ENABLED LITERATURE MINING AND LAB AUTOMATION MULTIPLYING R&D THROUGHPUT SIGNIFICANTLY
10.3.2
DATA ANALYTICS & REPORTING
10.3.2.1
REAL-WORLD EVIDENCE AND AI ANALYTICS TRANSFORMING STRATEGIC DECISION-MAKING ACROSS ORGANIZATIONS
10.3.3
MANUFACTURING & QUALITY ASSURANCE
10.3.3.1
PREDICTIVE QUALITY AI AND CONTINUOUS MANUFACTURING REDUCE BATCH FAILURES AND COMPLIANCE RISK
10.3.4
REGULATORY AFFAIRS
10.3.4.1
FDA AND EMA AI GUIDANCE CATALYZING REGULATORY SUBMISSION AUTOMATION AND PHARMACOVIGILANCE EFFICIENCY
11
AI IN LIFE SCIENCE MARKET, BY COMPONENT
126
11.2.1
AI SOFTWARE PLATFORMS BECOMING CORE INFRASTRUCTURE FOR LIFE SCIENCE DIGITAL TRANSFORMATION
11.3.1
SPECIALIZED AI SERVICES BRIDGING VALIDATION AND COMPLIANCE GAPS ACROSS LIFE SCIENCE ENTERPRISES
12
AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT
130
12.2
CLOUD-BASED SOLUTIONS
12.2.1
HYPERSCALE CLOUD INFRASTRUCTURE ACCELERATES LIFE SCIENCE AI SCALABILITY AND COLLABORATIVE RESEARCH
12.3
ON-PREMISE SOLUTIONS
12.3.1
DATA SOVEREIGNTY AND GXP COMPLIANCE SUSTAIN ON-PREMISE AI DEPLOYMENT ACROSS REGULATED ENVIRONMENTS
12.4.1
HYBRID ARCHITECTURES BALANCE REGULATORY COMPLIANCE, DATA SECURITY, AND AI SCALABILITY DEMANDS
13
AI IN LIFE SCIENCE MARKET, BY END USER
135
13.2.1
AI-POWERED CROS & CDMOS COMPETE ON SPEED, QUALITY, AND DATA INTELLIGENCE DIFFERENTIATION
13.3
PHARMACEUTICAL COMPANIES
13.3.1
AI EMBEDDED ACROSS DISCOVERY, TRIALS, AND COMMERCIAL OPERATIONS BROADLY BY PHARMA LEADERS
13.4
BIOTECHNOLOGY COMPANIES
13.4.1
AI-NATIVE BIOTECH MODELS COMPRESSING DRUG DISCOVERY TIMELINES FROM YEARS TO MONTHS
13.5
DIAGNOSTIC COMPANIES
13.5.1
AI-AUGMENTED DIAGNOSTICS ELEVATE SENSITIVITY AND THROUGHPUT ACROSS MOLECULAR AND IMAGING PLATFORMS
13.6
ACADEMIC & GOVERNMENT LABORATORIES
13.6.1
PUBLIC AI RESEARCH PROGRAMS AND OPEN SCIENCE INITIATIVES BUILD FOUNDATIONAL LIFE SCIENCE INFRASTRUCTURE
14
AI IN LIFE SCIENCE MARKET, BY OFFERING
143
14.2.1
INTEGRATED AI PLATFORMS COMPRESSING DRUG DEVELOPMENT TIMELINES ACROSS ENTIRE VALUE CHAINS
14.3
NICHE/POINT SOLUTIONS
14.3.1
DISEASE-SPECIFIC AI TOOLS DELIVER MEASURABLE OUTCOMES IN TARGETED RESEARCH WORKFLOWS
14.4.1
FOUNDATION MODELS AND GENERATIVE AI REDEFINE CORE SCIENTIFIC DISCOVERY CAPABILITIES
14.5.1
PROFESSIONAL AI SERVICES ENABLE COMPLIANT DEPLOYMENT ACROSS REGULATED LIFE SCIENCE ENVIRONMENTS
15
AI IN LIFE SCIENCE MARKET, BY REGION
149
15.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2.1
RECORD FDA APPROVALS AND FEDERAL FUNDING PROPEL AI MEDICAL DEVICE COMMERCIALIZATION
15.2.3.1
FEDERAL AI INVESTMENT AND SOVEREIGN COMPUTE STRATEGY CATALYZE LIFE SCIENCES INNOVATION
15.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2.1
PRESCRIPTION DIGITAL HEALTH APP FRAMEWORK PROPELS MARKET
15.3.3.1
NATIONAL AI-HEALTH DATA STRATEGY AND HEALTH DATA HUB ANCHOR DATA-DRIVEN LIFE SCIENCES
15.3.4.1
NHS TEN-YEAR PLAN POSITIONS AI AS CORE INFRASTRUCTURE FOR NATIONAL CARE TRANSFORMATION
15.3.5.1
NATIONAL RECOVERY PLAN DIGITIZATION FUNDING OPENS NEW HOSPITAL AI ADOPTION PATHWAYS
15.3.6.1
NATIONAL AI STRATEGY AND SNS DIGITIZATION ALIGN LIFE SCIENCES SECTOR WITH EU AI AMBITIONS
15.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2.1
NMPA HIGH-END DEVICE POLICY AND AI STANDARDIZATION BODY STREAMLINE AI COMMERCIALIZATION
15.4.3.1
PMDA ADAPTIVE AI FRAMEWORK AND MEDICAL DX REFORMS ACCELERATE SAMD COMMERCIALIZATION
15.4.4.1
INDIAAI MISSION AND NATIONAL HEALTH DATA INFRASTRUCTURE ENABLE POPULATION-SCALE AI DEPLOYMENT
15.4.5.1
MY HEALTH RECORD ECOSYSTEM AND TGA SAMD PATHWAYS UNDERPIN AI-READY DIGITAL INFRASTRUCTURE
15.4.6.1
K-MEDTECH ECOSYSTEM AND MFDS AI REGULATORY GUIDANCE PROPEL SMART HOSPITAL AI ADOPTION
15.4.7
REST OF ASIA PACIFIC
15.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2.1
RNDS NATIONAL HEALTH NETWORK PROVIDES DIGITAL BACKBONE FOR AI HEALTHCARE INTEGRATION
15.5.3.1
IMSS DIGITAL TRANSFORMATION AND NATIONAL AI STRATEGY DRIVE AI INTEGRATION INTO PUBLIC HEALTHCARE
15.5.4
REST OF LATIN AMERICA
15.6
MIDDLE EAST & AFRICA
15.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.3.1
VISION 2030 HEALTH SECTOR TRANSFORMATION PROGRAM DRIVES AI-ENABLED CARE DELIVERY AT SCALE
15.6.4.1
MALAFFI, NABIDH INTEROPERABILITY AND EMIRATI GENOME PROGRAMME ESTABLISH AI-READY DATA FOUNDATION
15.6.5.1
RISING DEMAND FOR TELEHEALTH & VIRTUAL CARE TO PROPEL MARKET
15.6.6.1
NATIONAL HEALTH INSURANCE FRAMEWORK AND DIGITAL HEALTH PROGRAMS CATALYZE AI MARKET ENTRY
15.6.7
REST OF MIDDLE EAST & AFRICA
16
COMPETITIVE LANDSCAPE
305
16.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
16.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET
16.4
MARKET SHARE ANALYSIS, 2025
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1
COMPANY FOOTPRINT
16.5.5.2
REGION FOOTPRINT
16.5.5.3
OFFERING FOOTPRINT
16.5.5.4
APPLICATION FOOTPRINT
16.5.5.5
END USER FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
16.7
VALUATION & FINANCIAL METRICS
16.8
BRAND/SOFTWARE COMPARISON
16.9
COMPETITIVE SCENARIO
16.9.1
PRODUCT/SERVICE LAUNCHES & APPROVALS
17
COMPANY PROFILES
328
17.1.1
NVIDIA CORPORATION
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS/SOLUTIONS OFFERED
17.1.1.3
RECENT DEVELOPMENTS
17.1.1.3.1
PRODUCT LAUNCHES & ENHANCEMENTS
17.1.1.3.3
OTHER DEVELOPMENTS
17.1.1.4.2
STRATEGIC CHOICES
17.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
17.1.5
DASSAULT SYSTÈMES SE
17.1.8
MICROSOFT CORPORATION
17.1.10
EUROFINS DISCOVERY
17.1.11
BENEVOLENTAI LIMITED
17.1.14
AIDOC MEDICAL LTD.
17.1.17
SOPHIA GENETICS SA
17.2.4
COUNTERFORCE HEALTH
18
RESEARCH METHODOLOGY
397
18.1.1
SECONDARY RESEARCH
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.1.2.2
KEY DATA FROM PRIMARY SOURCES
18.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.4
INSIGHTS FROM PRIMARY EXPERTS
18.2
RESEARCH METHODOLOGY DESIGN
18.3
MARKET SIZE ESTIMATION
18.5
RESEARCH ASSUMPTIONS
18.6
RESEARCH LIMITATIONS
18.6.1
METHODOLOGY-RELATED
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
TABLE 1
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2
AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3
AI IN LIFE SCIENCE MARKET: ROLE IN ECOSYSTEM
TABLE 4
CASE 1: GENERATIVE AI ACCELERATES DRUG DISCOVERY, CLINICAL RESEARCH, AND OPERATIONAL EFFICIENCY IN LIFE SCIENCES
TABLE 5
CASE 2: JOHNSON & JOHNSON EXPANDS AI INTEGRATION ACROSS DRUG DISCOVERY, SURGICAL INNOVATION, AND HEALTHCARE OPERATIONS
TABLE 6
CASE 3: AI-DRIVEN DRUG DISCOVERY AND CLINICAL OPTIMIZATION ACCELERATE INNOVATION IN LIFE SCIENCES
TABLE 7
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 8
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN LIFE SCIENCE MARKET
TABLE 14
AI IN LIFE SCIENCE MARKET: KEY PATENTS/PATENT APPLICATIONS
TABLE 15
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 16
KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 17
UNMET NEEDS IN AI IN LIFE SCIENCE MARKET
TABLE 18
END USER EXPECTATIONS IN AI IN LIFE SCIENCE MARKET
TABLE 19
AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 20
AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 21
AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 22
AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 23
AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 24
AI IN LIFE SCIENCE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 25
AI IN LIFE SCIENCE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 26
AI IN LIFE SCIENCE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 27
AI IN LIFE SCIENCE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 28
AI IN LIFE SCIENCE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 29
AI IN LIFE SCIENCE MARKET FOR SUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 30
AI IN LIFE SCIENCE MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 31
AI IN LIFE SCIENCE MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 32
AI IN LIFE SCIENCE MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 33
AI IN LIFE SCIENCE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION)
TABLE 34
AI IN LIFE SCIENCE MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 35
AI IN LIFE SCIENCE MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION)
TABLE 36
AI IN LIFE SCIENCE MARKET FOR IMAGE ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 37
AI IN LIFE SCIENCE MARKET FOR OTHER TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38
AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 39
AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 40
AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 41
AI IN LIFE SCIENCE MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 42
AI IN LIFE SCIENCE MARKET FOR MEDICAL IMAGING AND DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 43
AI IN LIFE SCIENCE MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 44
AI IN LIFE SCIENCE MARKET FOR PRECISION MEDICINE, BY REGION, 2024–2031 (USD MILLION)
TABLE 45
AI IN LIFE SCIENCE MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 46
AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 47
AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 48
AI IN LIFE SCIENCE MARKET FOR R&D SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 49
AI IN LIFE SCIENCE MARKET FOR DATA ANALYTICS AND REPORTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 50
AI IN LIFE SCIENCE MARKET FOR MANUFACTURING & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 51
AI IN LIFE SCIENCE MARKET FOR REGULATORY AFFAIRS, BY REGION, 2024–2031 (USD MILLION)
TABLE 52
AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 53
AI IN LIFE SCIENCE MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 54
AI IN LIFE SCIENCE MARKET FOR SERVICE, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 56
AI IN LIFE SCIENCE MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 57
AI IN LIFE SCIENCE MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 58
AI IN LIFE SCIENCE MARKET FOR HYBRID SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 59
AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 60
AI IN LIFE SCIENCE MARKET FOR CRO & CDMO, BY REGION, 2024–2031 (USD MILLION)
TABLE 61
AI IN LIFE SCIENCE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 62
AI IN LIFE SCIENCE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 63
AI IN LIFE SCIENCE MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 64
AI IN LIFE SCIENCE MARKET FOR ACADEMIC AND GOVERNMENT LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 65
AI IN LIFE SCIENCE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 66
AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 67
AI IN LIFE SCIENCE MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 68
AI IN LIFE SCIENCE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 69
AI IN LIFE SCIENCE MARKET FOR AI TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 70
AI IN LIFE SCIENCE MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 71
AI IN LIFE SCIENCE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 74
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 75
NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 76
NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 78
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 79
NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 80
NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 81
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 82
NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 83
US: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 84
US: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 85
US: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86
US: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 87
US: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 88
US: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 89
US: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 90
US: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 91
US: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 92
US: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 93
CANADA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 94
CANADA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 95
CANADA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 96
CANADA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 97
CANADA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 98
CANADA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 99
CANADA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 100
CANADA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101
CANADA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 102
CANADA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 103
EUROPE: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104
EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 105
EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 106
EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 107
EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 108
EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 109
EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 110
EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111
EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112
EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 113
EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114
GERMANY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 115
GERMANY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 116
GERMANY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117
GERMANY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 118
GERMANY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 119
GERMANY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 120
GERMANY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 121
GERMANY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122
GERMANY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 123
GERMANY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 124
FRANCE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 125
FRANCE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 126
FRANCE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127
FRANCE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128
FRANCE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 129
FRANCE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 130
FRANCE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131
FRANCE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132
FRANCE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 133
FRANCE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 134
UK: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 135
UK: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 136
UK: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 137
UK: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 138
UK: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 139
UK: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 140
UK: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141
UK: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142
UK: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 143
UK: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144
ITALY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 145
ITALY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 146
ITALY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147
ITALY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148
ITALY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 149
ITALY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 150
ITALY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151
ITALY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152
ITALY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 153
ITALY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 154
SPAIN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 155
SPAIN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 156
SPAIN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 157
SPAIN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158
SPAIN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 159
SPAIN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 160
SPAIN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161
SPAIN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162
SPAIN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 163
SPAIN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 164
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 165
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 166
REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167
REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 169
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 170
REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171
REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 173
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 174
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 176
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 177
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 180
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 181
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 182
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 184
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185
CHINA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 186
CHINA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 187
CHINA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188
CHINA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189
CHINA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 190
CHINA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 191
CHINA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192
CHINA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 193
CHINA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 194
CHINA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 195
JAPAN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 196
JAPAN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197
JAPAN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198
JAPAN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199
JAPAN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 200
JAPAN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 201
JAPAN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202
JAPAN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203
JAPAN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 204
JAPAN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 205
INDIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 206
INDIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 207
INDIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208
INDIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209
INDIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 210
INDIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 211
INDIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212
INDIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213
INDIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 214
INDIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 215
AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 216
AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 217
AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218
AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219
AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 220
AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 221
AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222
AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 223
AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 224
AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 225
SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 226
SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 227
SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228
SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229
SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 230
SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 231
SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232
SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 233
SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 234
SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 235
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 236
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 237
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 240
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 241
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 243
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 244
REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 245
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 247
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 248
LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 249
LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 251
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 252
LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253
LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 255
LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 256
BRAZIL: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 257
BRAZIL: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 258
BRAZIL: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259
BRAZIL: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 260
BRAZIL: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 261
BRAZIL: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 262
BRAZIL: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 263
BRAZIL: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264
BRAZIL: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 265
BRAZIL: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 266
MEXICO: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 267
MEXICO: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 268
MEXICO: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269
MEXICO: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270
MEXICO: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 271
MEXICO: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 272
MEXICO: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273
MEXICO: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274
MEXICO: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 275
MEXICO: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 276
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 277
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 278
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 279
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 281
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 282
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 285
REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 286
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 288
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 289
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 290
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 292
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 293
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 294
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 295
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 296
MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 297
GCC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298
GCC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 299
GCC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 300
GCC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301
GCC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302
GCC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 303
GCC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 304
GCC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305
GCC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 306
GCC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 307
GCC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 308
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 309
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 310
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 313
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 314
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 317
SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 318
UAE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 319
UAE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 320
UAE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321
UAE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322
UAE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 323
UAE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 324
UAE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 325
UAE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 326
UAE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 327
UAE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 328
REST OF GCC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 329
REST OF GCC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 330
REST OF GCC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 331
REST OF GCC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 332
REST OF GCC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 333
REST OF GCC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 334
REST OF GCC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 335
REST OF GCC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 336
REST OF GCC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 337
REST OF GCC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 338
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 339
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 340
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 341
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 342
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 343
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 344
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 345
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 346
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 347
SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 348
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 349
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 350
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 351
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 352
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 353
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 354
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 355
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 356
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 357
REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 358
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, JANUARY 2023–APRIL 2026
TABLE 359
AI IN LIFE SCIENCE MARKET: DEGREE OF COMPETITION
TABLE 360
AI IN LIFE SCIENCE MARKET: REGION FOOTPRINT
TABLE 361
AI IN LIFE SCIENCE MARKET: OFFERING FOOTPRINT
TABLE 362
AI IN LIFE SCIENCE MARKET: APPLICATION FOOTPRINT
TABLE 363
AI IN LIFE SCIENCE MARKET: END USER FOOTPRINT
TABLE 364
AI IN LIFE SCIENCE MARKET: TOOLS FOOTPRINT
TABLE 365
AI IN LIFE SCIENCE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 366
AI IN LIFE SCIENCE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
TABLE 367
AI IN LIFE SCIENCE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY OFFERING
TABLE 368
AI IN LIFE SCIENCE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY APPLICATION
TABLE 369
AI IN LIFE SCIENCE MARKET: SOLUTION LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 370
AI IN LIFE SCIENCE MARKET: DEALS, JANUARY 2023–APRIL 2026
TABLE 371
AI IN LIFE SCIENCE MARKET: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 372
NVIDIA CORPORATION: COMPANY OVERVIEW
TABLE 373
NVIDIA CORPORATION: PRODUCTS /SOLUTIONS OFFERED
TABLE 374
NVIDIA CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 375
NVIDIA CORPORATION: DEALS, JANUARY 2023– APRIL 2026
TABLE 376
NVIDIA CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 377
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 378
ILLUMINA, INC.: PRODUCTS /SOLUTIONS OFFERED
TABLE 379
ILLUMINA, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 380
ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 381
TEMPUS AI, INC.: COMPANY OVERVIEW
TABLE 382
TEMPUS AI, INC.: PRODUCTS OFFERED
TABLE 383
TEMPUS AI, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 384
TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 385
RECURSION: COMPANY OVERVIEW
TABLE 386
RECURSION: PRODUCTS /SOLUTIONS OFFERED
TABLE 387
RECURSION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 388
RECURSION: DEALS, JANUARY 2023– APRIL 2026
TABLE 389
RECURSION: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 390
DASSAULT SYSTÈMES SE: COMPANY OVERVIEW
TABLE 391
DASSAULT SYSTÈMES SE: PRODUCTS OFFERED
TABLE 392
DASSAULT SYSTÈMES SE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 393
DASSAULT SYSTÈMES SE: DEALS, JANUARY 2023–APRIL 2026
TABLE 394
DASSAULT SYSTÈMES SE: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 395
SCHRÖDINGER, INC.: COMPANY OVERVIEW
TABLE 396
SCHRÖDINGER, INC.: PRODUCTS /SOLUTIONS OFFERED
TABLE 397
SCHRÖDINGER, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 398
SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2023-APRIL 2026
TABLE 399
DATA4CURE, INC.: COMPANY OVERVIEW
TABLE 400
DATA4CURE, INC.: PRODUCTS OFFERED
TABLE 401
DATA4CURE, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 402
DATA4CURE, INC.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 403
MICROSOFT CORPORATION: COMPANY OVERVIEW
TABLE 404
MICROSOFT CORPORATION: PRODUCTS OFFERED
TABLE 405
MICROSOFT CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 406
MICROSOFT CORPORATION: DEALS, JANUARY 2023–APRIL 2026
TABLE 407
MICROSOFT CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 408
INSILICO MEDICINE: COMPANY OVERVIEW
TABLE 409
INSILICO MEDICINE: PRODUCTS /SERVICES OFFERED
TABLE 410
INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 411
INSILICO MEDICINE: DEALS, JANUARY 2023–APRIL 2026
TABLE 412
INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2023-APRIL 2026
TABLE 413
INSILICO MEDICINE: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 414
EUROFINS DISCOVERY: COMPANY OVERVIEW
TABLE 415
EUROFINS DISCOVERY: PRODUCTS OFFERED
TABLE 416
EUROFINS DISCOVERY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 417
EUROFINS DISCOVERY: DEALS, JANUARY 2023–APRIL 2026
TABLE 418
BENEVOLENTAI LIMITED: COMPANY OVERVIEW
TABLE 419
BENEVOLENTAI LIMITED: PRODUCTS OFFERED
TABLE 420
BENEVOLENTAI LIMITED: DEALS, JANUARY 2023–APRIL 2026
TABLE 421
OWKIN: COMPANY OVERVIEW
TABLE 422
OWKIN: PRODUCTS OFFERED
TABLE 423
OWKIN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 424
OWKIN: DEALS, JANUARY 2023–APRIL 2026
TABLE 425
OWKIN: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 426
PATHAI: COMPANY OVERVIEW
TABLE 427
PATHAI: PRODUCTS OFFERED
TABLE 428
PATHAI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 429
PATHAI: DEALS, JANUARY 2023–APRIL 2026
TABLE 430
AIDOC MEDICAL LTD.: COMPANY OVERVIEW
TABLE 431
AIDOC MEDICAL LTD.: PRODUCTS OFFERED
TABLE 432
AIDOC MEDICAL LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 433
AIDOC MEDICAL LTD.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 434
QURE.AI: COMPANY OVERVIEW
TABLE 435
QURE.AI: PRODUCTS OFFERED
TABLE 436
QURE.AI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 437
DEEP GENOMICS: COMPANY OVERVIEW
TABLE 438
DEEP GENOMICS: PRODUCTS OFFERED
TABLE 439
DEEP GENOMICS: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 440
SOPHIA GENETICS SA: COMPANY OVERVIEW
TABLE 441
SOPHIA GENETICS SA: PRODUCTS OFFERED
TABLE 442
SOPHIA GENETICS SA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026
TABLE 443
SOPHIA GENETICS SA: DEALS, JANUARY 2023–APRIL 2026
TABLE 444
UNLEARN.AI: COMPANY OVERVIEW
TABLE 445
UNLEARN.AI: PRODUCTS OFFERED
TABLE 446
UNLEARN.AI: DEALS, JANUARY 2023–APRIL 2026
TABLE 447
VERGE GENOMICS: COMPANY OVERVIEW
TABLE 448
VERGE GENOMICS: PRODUCTS OFFERED
TABLE 449
VERGE GENOMICS: DEALS, JANUARY 2023–APRIL 2026
TABLE 450
SYNTHIO LABS LTD: COMPANY OVERVIEW
TABLE 451
BIOPTIMUS: COMPANY OVERVIEW
TABLE 452
KARYON BIO: COMPANY OVERVIEW
TABLE 453
COUNTERFORCE HEALTH: COMPANY OVERVIEW
TABLE 454
PROMISE BIO: COMPANY OVERVIEW
FIGURE 2
GLOBAL AI IN LIFE SCIENCE MARKET, 2024–2031
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2023–2026
FIGURE 4
DISRUPTIONS INFLUENCING GROWTH OF AI IN LIFE SCIENCE MARKET
FIGURE 5
HIGH-GROWTH SEGMENTS IN AI IN LIFE SCIENCE MARKET, 2026–2031
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN LIFE SCIENCE MARKET DURING FORECAST PERIOD
FIGURE 7
GROWING ADOPTION OF PRECISION MEDICINE AND AI IN DRUG DISCOVERY TO DRIVE MARKET
FIGURE 8
CLINICAL APPLICATIONS IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 9
JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10
AI IN LIFE SCIENCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11
AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 12
AI IN LIFE SCIENCE MARKET: VALUE CHAIN ANALYSIS (2025)
FIGURE 13
AI IN LIFE SCIENCE MARKET: ECOSYSTEM ANALYSIS
FIGURE 14
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 15
TOTAL FUNDING OF PLAYERS IN AI IN LIFE SCIENCE MARKET
FIGURE 16
JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN LIFE SCIENCE MARKET
FIGURE 17
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN LIFE SCIENCE MARKET (JANUARY 2015 TO DECEMBER 2025)
FIGURE 18
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 19
KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 20
NORTH AMERICA: AI IN LIFE SCIENCE MARKET SNAPSHOT
FIGURE 21
ASIA PACIFIC: AI IN LIFE SCIENCE MARKET SNAPSHOT
FIGURE 22
REVENUE ANALYSIS OF KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2021–2025 (USD MILLION)
FIGURE 23
AI IN LIFE SCIENCE MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 24
AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 25
AI IN LIFE SCIENCE MARKET: COMPANY FOOTPRINT
FIGURE 26
AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 27
EV/EBITDA OF KEY VENDORS
FIGURE 28
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 29
AI IN LIFE SCIENCE MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS
FIGURE 30
NVIDIA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 31
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 32
TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 33
RECURSION: COMPANY SNAPSHOT (2024)
FIGURE 34
DASSAULT SYSTÈMES SE: COMPANY SNAPSHOT (2025)
FIGURE 35
SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2024)
FIGURE 36
MICROSOFT CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 37
SOPHIA GENETICS SA: COMPANY SNAPSHOT (2025)
FIGURE 38
RESEARCH DESIGN
FIGURE 39
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 40
BOTTOM-UP APPROACH
FIGURE 41
TOP-DOWN APPROACH
FIGURE 42
CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 43
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 44
DATA TRIANGULATION
Methodology
The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.
AI in Life Science Market : Top-Down and Bottom-Up Approach
Data Triangulation
After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market.
Market Definition
AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.
Key Stakeholders
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs) & Clinical Trial Partners
- Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
- Digital Health & AI Solution Providers
- Cloud & Data Infrastructure Providers
- Data Analytics & Software Platform Providers
- Payers & Insurance Companies
- Regulatory & Compliance Bodies (e.g., FDA, EMA)
- Academic & Research Institutions
- Patients & End Users
- Technology Integrators & Consulting Firms
Report Objectives
- To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company.
Regional Analysis
- Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the AI in Life Science Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Previous Next
